EdiGENE is a biotech company that develops therapeutics using its proprietary technology CRISPR-GNDM (guide nucleotide-directed modulation) for the treatment of genetic disorders. The Company’s technology platform normalizes levels of gene expression without cutting the DNA or RNA.
|HQ||Cambridge, MA, US||Map|
|Employees (est.) (Jan 2021)||25|
EdiGENE total Funding
EdiGENE latest funding size
Time since last funding
|3 months ago|
|WI Harper Group, SBI Investment, Green Pine Capital, Mizuho Capital, SMBC Venture Capital, IDG Capital, Huagai Capital, Lilly Asia Ventures, Sequoia Capital China, Lilly Asia Venture, Green Pine Capital Partners, FUJIFILM, UTokyo Innovation Platform Co., Fast Track Initiative, CareNet Group, 3H Health Investment, Alwin Capital, Kunlun Capital|
EdiGENE has 12 Twitter Followers. The number of followers has increased 9.1% month over month and increased 9.1% quarter over quarter
When was EdiGENE founded?
EdiGENE was founded in 2015.
How many employees does EdiGENE have?
EdiGENE has 25 employees.
Who are EdiGENE competitors?
Competitors of EdiGENE include Pantherna Therapeutics, Pluristem Therapeutics and Freeline.
Where is EdiGENE headquarters?
EdiGENE headquarters is located at F18, Riverview II, 245 First St, Cambridge.
Where are EdiGENE offices?
EdiGENE has an office in Cambridge.
How many offices does EdiGENE have?
EdiGENE has 1 office.
Receive alerts for 300+ data fields across thousands of companies